Navigation Links
Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
Date:7/30/2013

CAMBRIDGE, England, July 30, 2013 /PRNewswire/ --

Designation granted by US FDA for the treatment of trigeminal neuralgia

Convergence Pharmaceuticals Limited ("Convergence" or "the company"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, is pleased to announce that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation by the US Food and Drug Administration for the treatment of trigeminal neuralgia (TN). Orphan-drug designation gives Convergence various incentives and advantages in the development of '802, including the potential availability of certain grants for clinical studies and assistance from the FDA with clinical protocol design. Furthermore orphan drug designation grants US market exclusivity, distinct from other types of exclusivity, for seven years if '802 is approved.

TN is a very severe form of facial pain that is experienced in short bursts or attacks called paroxysms. The International Association for the Study of Pain (IASP) defines TN as sudden, severe, brief, stabbing, recurrent episodes of pain usually on one side of the face and can be provoked by light touch. The pain follows one or more branches of the trigeminal nerve which provides nerve sensation from the mouth, face and the front of the scalp.

'802 is a novel small molecule that penetrates the central nervous system (CNS) and blocks Navs in a highly state-dependent fashion, while exhibiting selectivity against the 1.7 subtype. '802 is currently undergoing clinical evaluation in an innovative Phase II trial. An interim analysis from the trial reported in March that 70% of patients showed a successful response and were subsequently randomised into the double-blind treatment period. '802 was safe and well tolerated in these patients.

Clive Dix, Chief Executive Officer of Convergence Pharmaceu
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia
2. Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II Trigeminal Neuralgia Study
3. Eighth Annual WLSA Convergence Summit Focuses on Moving from Innovation to Adoption
4. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
5. Webcast Alert: Isis Pharmaceuticals Second Quarter 2013 Financial Results Conference Call
6. Insight Pharmaceuticals Considers Bananacin -- Banana-Flavored Anacin Tablets -- After Worlds Oldest Man Credits Combo As Secret To Long Life
7. Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
8. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2013 Financial Results
9. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
10. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, August 1
11. Auxilium Pharmaceuticals to Announce Second Quarter 2013 Results and Conduct Conference Call on Thursday, August 1, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Dec. 9, 2010 Customers using Elekta,s ... with seamless integration to Varian,s TrueBeam ™ ... to this linear accelerator is the most recent ... and the delivery systems of other cancer management ...
... Conn., Dec. 9, 2010 Boehringer Ingelheim Pharmaceuticals, Inc. ... the phase IIb/III LUX-Lung 1 trial show that afatinib ... 1.0 month for placebo) in progression-free survival (PFS) in ... to have an epidermal growth factor receptor (EGFR) mutation.(1) ...
Cached Medicine Technology:Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity 2Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity 3New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 2New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 3New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 4New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 5
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
(Date:4/17/2014)... and their partners have found that their proprietary microbicide ... of multiple sexually transmitted infections (STIs) in both the ... 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded study ... effective against multiple strains of HIV, and has a ... viruses of at least eight hours prior to exposure. ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... The following is a,statement from Matthew L. Myers, ... and Ohio legislators have abandoned Ohio,s kids,and put the ... to,raid funds from the Ohio Tobacco Prevention Foundation. This ... children will become addicted to,tobacco, more Ohio citizens will ...
... April 8, 2008 The Center,for Connected ... of the,nation,s leading integrated health care delivery ... studies conducted at Partners-affiliated,hospitals, including Massachusetts General ... of connected health technologies.,These study findings, presented ...
... to two botanical functional ... ingredients, GLPH-1(TM) and PPL-240(TM), BIG HORN, Wyo., April ... validated and organically derived,ingredients for use in foods and ... GLPH-1(TM), an immune booster, and,PPL-240(TM), a photoprotective antioxidant, at ...
... output, breathing improve, researchers say , , TUESDAY, April 8 ... is enough to boost the cardiac performance and breathing ... finds. , This slightly more strenuous exercise program -- ... failure -- works at least as well as the ...
... What do you learn by looking at the spines of ... of researchers behind the Twin Spine Study, you find compelling ... of genetics than physical strain. , The findings of the ... have led to a dramatic paradigm shift in the way ...
... in the developing world is the litany of tropical ... by the public health community. This is the ... published by ASM Press. , Some of the worst ... ignored. Parasitic and bacterial diseases such as hookworm, ...
Cached Medicine News:Health News:Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment 2Health News:Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment 3Health News:Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment 4Health News:Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008 2Health News:Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008 3Health News:A Month of Exercise Helps Ease Heart Failure 2Health News:Award-winning study says back pain may be in your genes 2Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
ZyDoc offers a full medical transcription and documentation solution....
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: